GlaxoSmithKline on Monday announced several changes to the membership of its board and committees, as well as the creation of a science committee, which will all take effect January 1. The drugmaker said the science committee was established "to provide oversight of, and expertise to the board in relation to, GlaxoSmithKline's R&D pipeline and scientific research strategy." The moves come as Emma Walmsley is slated to take over from Andrew Witty as CEO of GlaxoSmithKline at the end of March.
The science committee will be headed by non-executive director and former FDA chief scientist Jesse Goodman. Other members of the committee will include Roy Anderson, former Merck & Co. chief financial officer Judy Lewent and a further scientific and medical expert who has yet to be recruited.
As previously announced, the company said Walmsley will join the board as an executive director on January 1, as will R&D president Patrick Vallance, ahead of the upcoming retirement of GlaxoSmithKline's global vaccines chief and board member Moncef Slaoui, who has served as chairman of the R&D division. Meanwhile, board members Vivienne Cox and Urs Rohner will join the remuneration committee and the nomination committee, respectively.
To read more Top Story articles, click here.